Robert A. Lenz Sells 30,788 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Robert A. Lenz sold 30,788 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total value of $363,606.28. Following the sale, the insider now owns 339,205 shares of the company’s stock, valued at $4,006,011.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $12.92 on Friday. Neumora Therapeutics, Inc. has a one year low of $8.33 and a one year high of $21.00. The firm has a 50 day simple moving average of $11.74 and a 200 day simple moving average of $11.45.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, meeting analysts’ consensus estimates of ($0.37). Sell-side analysts forecast that Neumora Therapeutics, Inc. will post -1.51 EPS for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new position in shares of Neumora Therapeutics in the first quarter valued at approximately $10,354,000. Baker BROS. Advisors LP bought a new stake in Neumora Therapeutics during the 1st quarter worth approximately $8,715,000. Callan Capital LLC increased its position in Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after acquiring an additional 456,207 shares during the period. Artal Group S.A. raised its stake in shares of Neumora Therapeutics by 14.5% during the first quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock valued at $40,206,000 after acquiring an additional 371,350 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Neumora Therapeutics by 474.1% during the second quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company’s stock worth $2,316,000 after purchasing an additional 194,559 shares during the period. 47.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a report on Thursday, September 12th. Finally, Mizuho initiated coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They issued an “outperform” rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Neumora Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $22.11.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.